Vanda V. West-Ward: This Time, Dosage Adjustment Claims Are Patent Eligible Subject Matter | Latest News RSS feed

Vanda V. West-Ward: This Time, Dosage Adjustment Claims Are Patent Eligible Subject Matter - Latest News


Vanda v. West-Ward: This Time, Dosage Adjustment Claims are Patent Eligible Subject Matter

The Federal Circuit’s decision in Vanda Pharmaceuticals Inc. v. West-Ward ... claims that merely apply a law of nature are not patent-eligible either. Id. This decision highlights the difficulty ... read more

Hikma and West-Ward v. Vanda – Are Methods of Medical Treatment Patent-Eligible?

s decision in Vanda v. West-Ward ... dose range of an immunosuppressive drug by measuring the blood concentration of its metabolite. However, it contained language explicitly stating that claims ... read more

Federal Circuit: Hardening the Line on Method-of-Treatment Claims

This decision here is the next in a series of decisions creating a hard rule that method-of-treatment claims are patent eligible. See Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals ... to ... read more

Looking for another news?


Treatment Method Patents After Fed. Circ. Vanda Ruling

The Vanda claims were held to be patent-eligible because the subject matter of the method steps ... where “the claims essentially control a dosage of radiation based on the results of testing for a ... read more


USPTO Guidance on Subject Matter Eligibility of Method of Treatment Claims

On June 7, 2018, the USPTO issued a memorandum to patent examiners based on the recent Federal Circuit decision in Vanda Pharmaceuticals Inc. v. West-Ward ... claims of U.S. Patent No. 8,586,610 (the ... read more

Methods For Using Natural Compounds Can Be Patent-Eligible

Applying the Alice two-part test[7], the district court determined that all of the asserted claims were (1) directed to patent-ineligible subject matter under 35 ... omitted). [13] Vanda ... read more

Patent Eligibility Remains Uncertain, Even After Recent Efforts to Bring Clarity

the courts in recent years have tried to reign in the scope of the patent right by limiting the scope of patent-eligible subject matter under 35 U.S.C. §101. In each of these cases, the decision ... read more

Federal Circuit Held Vanda’s Method of Treatment Claims Are “Application of Nature Law”—While Chief Judge Prost Dissented

On April 13, 2018, in a split decision, the Federal Circuit held that Vanda Pharmaceuticals Inc.’s method of treatment claims are directed to patent-eligible subject matter under step one of the Mayo ... read more

Applicability of §101 Challenges in ANDA Pharmaceutical Litigation

Turning to the second prong, the court found that merely reciting an improvement of not requiring dose adjustment ... claims patent-eligible subject matter, and the court granted the motion to dismiss ... read more

Federal Circuit Circumvents Mayo/Alice Rule in Vanda v. West-Ward

In other words, what is patent-eligible ... the dosage level where the test results suggest that such an adjustment is advisable.” The majority again discussed the importance of the specificity of the ... read more

USPTO issues guidance on patent eligibility of method of treatment claims in light of Vanda Pharmaceuticals

West-Ward Pharmaceuticals ... Thereafter the memo states that Vanda illustrates several important points regarding the subject matter eligibility analysis. First, the Federal Circuit evaluated the ... read more

Vanda on Rehearing: Will the Federal Circuit Defy SCOTUS?

Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd., 887 F ... What the majority suggests, but does not say, is that Mayo’s claims would be patent eligible if they added one more step of injecting the ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us